These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12000860)

  • 21. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
    Chiriva-Internati M; Cobos E; Cannon MJ
    Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
    Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
    J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding dendritic cell immunotherapy in ovarian cancer.
    Drakes ML; Stiff PJ
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for gynaecological malignancies.
    Coukos G; Conejo-Garcia JR; Roden RB; Wu TC
    Expert Opin Biol Ther; 2005 Sep; 5(9):1193-210. PubMed ID: 16120050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Checkpoint inhibitors in immunotherapy of ovarian cancer.
    Wang DH; Guo L; Wu XH
    Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor antigen targets and tumor immunotherapy.
    Mufson RA
    Front Biosci; 2006 Jan; 11():337-43. PubMed ID: 16146735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor infiltrating lymphocytes in ovarian cancer.
    Gasparri ML; Attar R; Palaia I; Perniola G; Marchetti C; Di Donato V; Farooqi AA; Papadia A; Panici PB
    Asian Pac J Cancer Prev; 2015; 16(9):3635-8. PubMed ID: 25987014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Past, present and future targets for immunotherapy in ovarian cancer.
    Schwab CL; English DP; Roque DM; Pasternak M; Santin AD
    Immunotherapy; 2014; 6(12):1279-93. PubMed ID: 25524384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
    Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
    Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.
    Lavoué V; Cabillic F; Toutirais O; Thedrez A; Dessarthe B; de La Pintière CT; Daniel P; Foucher F; Bauville E; Henno S; Burtin F; Bansard JY; Levêque J; Catros V; Bouet-Toussaint F
    Int J Cancer; 2012 Aug; 131(4):E449-62. PubMed ID: 22095289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian cancer immunotherapy: opportunities, progresses and challenges.
    Liu B; Nash J; Runowicz C; Swede H; Stevens R; Li Z
    J Hematol Oncol; 2010 Feb; 3():7. PubMed ID: 20146807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian cancer and the immune system - The role of targeted therapies.
    Turner TB; Buchsbaum DJ; Straughn JM; Randall TD; Arend RC
    Gynecol Oncol; 2016 Aug; 142(2):349-56. PubMed ID: 27174875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in Ovarian Cancer.
    Wang W; Liu JR; Zou W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.